KDventures: Umecrine Secures NCE protection to 2042, unlocking broader commercial upside - Redeye
KDventures announced that its portfolio company Umecrine Cognition has received two notices of allowance from the USPTO for its second-generation GAMSA compounds, GR3053 and GR3055. This creates a pipeline potential for Umecrine.
ANNONS
KDventures announced that its portfolio company Umecrine Cognition has received two notices of allowance from the USPTO for its second-generation GAMSA compounds, GR3053 and GR3055. This creates a pipeline potential for Umecrine.